Introduction
progression may help identify targets for future therapeutic strategies to improve clinical outcome.
In contrast to other solid tumours, central chondrosarcomas harbour relatively few, consistent, numerical genomic alterations; however, the amplification of 12q13 [5, 6] and deletion of 9p21 [7] [8] [9] are two consistent genetic aberrations. Using array comparative genomic hybridization (CGH), we previously showed amplification of 12q13 in 6 of 21 (29%) central chondrosarcomas, which correlated with high histological grade [6] , as was also suggested by others [9] . Several genes in this region are of importance for cell cycle control including CDK4 and MDM2, players in the pRb and p53 pathway, respectively. Defects in these pathways are found at high rates in almost all types of human cancer [10, 11] . Combining the array CGH results with those of our genome-wide expression profiling experiments showed overexpression of the CDK4 proto-oncogene in tumours with 12q13 amplification [6] . [12] . Despite LOH of 13q14 has been found in a subset of chondrosarcoma [13, 14] , i.e. in 10 of 28 tumours by Yamaguchi et al. [5] , pRb mutations were not found [5] . Ropke et al. showed pRb expression in 16 of 17 chondrosarcomas by immunohistochemistry [14] .
CDK4 controls progression through the cell cycle by regulating the transit of the cell through the G1 restriction point. This occurs by hyper-phosphorylation of pRb, leading to the release of E2F transcription factors. To accomplish this, CDK4 forms a complex with cyclin D1. This complex is tightly regulated by the inhibitory protein CDKN2A (CDKN2A/p16), which is encoded by the INK4A-ARF locus located on chromosome 9p21. Inhibition of the pRb-mediated cell cycle control through amplification of cyclin D1 or CDK4 and/or loss of expression of CDKN2A/p16/INK4A has been observed in many tumours
We and others previously demonstrated that loss of CDKN2A/p16 protein expression is correlated with increasing histological grade in central chondrosarcoma [7, 15, 16] . Cyclin D1 was previously shown to be expressed in 25 of 34 (73%) highgrade central chondrosarcomas [17] .
In addition to CDK4, the 12q13 gene region harbours the MDM2 gene that is frequently found to be co-amplified with CDK4 [18] [11] . p53 mutations have been found in a subset of chondrosarcomas, and are mostly associated with aggressive behaviour (reviewed in Rozeman et al., 2002 [19] ). Amplification of MDM2 is frequently found in sarcomas (reviewed in Sandberg et al., 2004 [20] [21] . However, these results could not be reproduced in other series [6] . c-MYC among others, drives cells into S phase [22] . Slight differences in c-MYC expression were reported between enchondromatosis-related and solitary chondrosarcomas [23] . [26] .
Overexpressing and short hairpin (sh) RNA lentiviral vectors
The CDKN2A/p16-expressing lentiviral vector (kindly provided by Dr. R. Hoeben, department of Molecular Cell Biology, Leiden University Medical Center) has been described previously [27] . To generate vectors expressing shRNA against CDK4, oligonucleotides (for sequences see Supplementary  Table S1 ) were cloned into the pTER vector [28] . Subsequently, fragments containing the H1-promoter and cloned oligonucleotides were recloned into the lentiviral pRRL-CMV-GFP vector [29] . Production of lentiviruses by transfection into 293T cells has been described previously [29] . For 
Clonogenic survival assay
Cells (1000, 5000 and 10000) were plated on 6-well plates. Cells were allowed to form colonies over a period of 14 days and subsequently fixed with methanol/acetic acid and stained using Giemsa.
Patient material
Conventional central chondrosarcomas were selected based on accepted clinicopathological and radiological criteria [1] . 
Quantitative real-time reverse transcriptase PCR (qPCR)
Fresh frozen tumour tissue was available for RNA isolation, performed as described previously, from 34 cases [30] . Growth plate samples (n ϭ 4) were used as controls. mRNA expression of CDK4, MDM2 and c-MYC (for primer sequences see Supplementary Table S3) were studied using quantitative RT-PCR, as previously described [31] . Four control genes (CYPA, CPSF6, SRPR and HNRPH1) were selected because of their invariable expression in chondrosarcoma [31] . As a reference for normalization and statistical analysis, a mixture of 15 cell lines [23] was included. Normalization was performed using GENORM [32] . 
Immunohistochemistry (IHC)

Results
Functional analysis of the pRb pathway in vitro
Immunoblotting showed an absence of CDKN2A/p16 in all three chondrosarcoma cell lines, while pRb was mainly present in its inactive, hyper-phosphorylated form (Fig. 1A) Supplementary Fig. S1 ). shRNA targeting CDK4 in the chondrosarcoma cell lines and MCF7 was effective (Fig. 1E) .
Decrease in hyper-phosphorylated pRb expression is indicative of cell cycle arrest and was found upon knockdown of CDK4 in all the
Fig. 1 Immunoblot analysis of chondrosarcoma cell lines upon the overexpression of CDKN2A/p16 (A) or knock-down of CDK4 (E). (B) The characteristic band shift of pRb on 7.5% gel in the chondrosarcoma cell lines SW1353 and OUMS27. VH10 that was density-arrested and serum starved and subsequently reseeded in 20% serum (ϩ) served as a control for hyper-phosporylated pRb. (F) The decreased ability of OUMS27 to form colonies after knockdown of CDK4. Relative cell numbers (C, G) and cell viability (D, H) compared with controls are shown (both measured 6 days after treatment). *significant differences. cell lines, although to a lesser extent in OUMS27. Again, a reduction of total pRb with hypo-phosphorylation of existing pRb is observed. Enhanced degradation of pRb has been described previously after the inhibition of cyclin D1 in p21
WAF1 expressing lung cancer cells [33] . Interestingly, the CH2879 cells, in which the effect on pRb levels is most prominent (Fig. 1E) Fig. 1F ).
Expression of pRb and p53 components in clinical samples
Quantitative PCR The increase in CDK4 and MDM2 mRNA expression correlates with increasing histological grade ( Fig. 2A and C Supplementary Fig. S3 ). Table 2 . Nuclear expression of CDK4 and MDM2 protein, as illustrated by Figure 2B and D, was correlated with increasing histological grade in chondrosarcomas (Pearson's R ϭ 0.368, P ϭ 0.009 and Fig. 2E , R ϭ 0.356, P ϭ 0.007, respectively). Of the 29 high-grade chondrosarcomas that were previously studied for CDKN2A/p16 protein expression [15] (Table 3) and that were selected for further study, cyclin D1 was expressed in 62% (17/27 [7, 16] and by us [15] . We now show the functional implications of the p16 loss in central chondrosarcoma by overexpressing p16 in three p16-negative chondrosarcoma cell lines. We found decreased cell growth upon p16 overexpression, which is probably caused by senescence, since increased apoptosis was not observed (data not shown).
shown). In enchondromatosis-related tumours, c-MYC mRNA expression was significantly higher than in solitary tumours (Student's t-test P ϭ 0.011, confidence interval [Ϫ0.80; Ϫ0.116];
Immunohistochemistry
Results of CDK4, MDM2 and c-MYC staining on the series of 90 FFPE sections are shown in
Other players in the pRb pathway are also affected in central chondrosarcoma, as was also reported previously [7, [14] [15] [16] [17] 35] (Fig. 3) . Surprisingly, p21 expression was also shown to be associated with increasing grade in chondrosarcoma [36] . The reported amplification of the c-MYC locus (8q24) [21] could not be verified in our previous arrayCGH experiments [6] . cDNA microarray demonstrated differences in mRNA expression of the oncogene c-MYC in enchondromatosis-related versus solitary tumours [23] , which we confirmed in the present study using qPCR. c-MYC overexpression is observed in a large number of malignancies [22] [5, 13, 14] , pRb mutations were not found [5] . Moreover 
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